These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10218235)

  • 1. Red blood cells, plasma, and other new apheresis-derived blood products: improving product quality and donor utilization.
    Smith JW; Gilcher RO
    Transfus Med Rev; 1999 Apr; 13(2):118-23. PubMed ID: 10218235
    [No Abstract]   [Full Text] [Related]  

  • 2. [The Medical Products Agency should supervise blood production. Disagreement concerning men who had sexual contacts with men has brought matters to a head].
    Söderström T
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1894. PubMed ID: 22111225
    [No Abstract]   [Full Text] [Related]  

  • 3. The quality of blood products in Mississippi takes another leap forward.
    Jett PL
    J Miss State Med Assoc; 1999 Nov; 40(11):390-1. PubMed ID: 10568090
    [No Abstract]   [Full Text] [Related]  

  • 4. Standardization of the red cell product.
    Sweeney JD
    Transfus Apher Sci; 2006 Apr; 34(2):213-8. PubMed ID: 16510312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quality standards and quality control of plasma].
    Fürst G
    Beitr Infusionsther; 1991; 28():49-55. PubMed ID: 1725660
    [No Abstract]   [Full Text] [Related]  

  • 6. [Do we have a good blood supply?].
    Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Oct; 56(10):1349-51. PubMed ID: 24162028
    [No Abstract]   [Full Text] [Related]  

  • 7. [Labile blood products and their preparation].
    Chabanel A; Folléa G
    Rev Prat; 2001 Jun; 51(12):1306-10. PubMed ID: 11503503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring donor and product factors and their impact on red cell post-transfusion outcomes.
    Ning S; Heddle NM; Acker JP
    Transfus Med Rev; 2018 Jan; 32(1):28-35. PubMed ID: 28988603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Checking of blood product in hospital].
    Girard A
    Transfus Clin Biol; 2004 Oct; 11(4):205-9. PubMed ID: 15564102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blood components: indication and notice of transfusion].
    Sekiguchi S
    Nihon Rinsho; 1997 Sep; 55(9):2205-13. PubMed ID: 9301278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of autotransfusion in spine surgery: comparison of autotransfusion alone and with hemodilution and apheresis.
    Blais RE; Hadjipavlou AG; Shulman G
    Spine (Phila Pa 1976); 1996 Dec; 21(23):2795-800. PubMed ID: 8979328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice.
    Vamvakas EC
    Transfusion; 2013 Apr; 53(4):888-901. PubMed ID: 22882177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Production and consumption of blood and blood products in Norway. Factors of quality assurance in transfusion medicine].
    Heier HE
    Tidsskr Nor Laegeforen; 1993 Jan; 113(1):18-22. PubMed ID: 8424244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood products].
    Montloin A
    Rev Infirm; 1992 Mar; 42(6):33-41. PubMed ID: 1598492
    [No Abstract]   [Full Text] [Related]  

  • 15. Leukocyte reduction of blood components: public policy and new technology.
    Dzik S; Aubuchon J; Jeffries L; Kleinman S; Manno C; Murphy MF; Popovsky MA; Sayers M; Silberstein LE; Slichter SJ; Vamvakas EC
    Transfus Med Rev; 2000 Jan; 14(1):34-52. PubMed ID: 10669939
    [No Abstract]   [Full Text] [Related]  

  • 16. Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products. British Committee for Standards in Haematology.
    Howell C; Douglas K; Cho G; El-Ghariani K; Taylor P; Potok D; Rintala T; Watkins S
    Transfus Med; 2015 Apr; 25(2):57-78. PubMed ID: 26013470
    [No Abstract]   [Full Text] [Related]  

  • 17. Apheresis for collection of Ebola convalescent plasma in Liberia.
    Brown JF; Rowe K; Zacharias P; van Hasselt J; Dye JM; Wohl DA; Fischer WA; Cunningham CK; Thielman NM; Hoover DL
    J Clin Apher; 2017 Jun; 32(3):175-181. PubMed ID: 27393614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Red cell collection by apheresis technology.
    Meyer D; Bolgiano DC; Sayers M; Price T; Benson D; Slichter SJ
    Transfusion; 1993 Oct; 33(10):819-24. PubMed ID: 8236422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The six questions of pathogen reduction technology: an overview of current opinions.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2008 Aug; 39(1):51-7. PubMed ID: 18614401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of a strategy to prevent TRALI in a regional blood centre.
    Insunza A; Romon I; Gonzalez-Ponte ML; Hoyos A; Pastor JM; Iriondo A; Hermosa V
    Transfus Med; 2004 Apr; 14(2):157-64. PubMed ID: 15113380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.